

Olaratumab and doxorubicin versus doxorubicin alone
sarcoma: an open-label phase 1b and randomised phase

Lancet, The

388, 488-497

DOI: [10.1016/s0140-6736\(16\)30587-6](https://doi.org/10.1016/s0140-6736(16)30587-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin. <i>Cancer Management and Research</i> , 2016, Volume 8, 95-104.	0.9	12
2	Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma. <i>Sarcoma</i> , 2016, 2016, 1-7.	0.7	3
3	SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1213-1220.	1.2	34
4	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. <i>Cancer Medicine</i> , 2016, 5, 3437-3444.	1.3	20
5	Olaratumab – really a breakthrough for soft-tissue sarcomas?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 534-536.	12.5	8
6	Olaratumab in soft-tissue sarcomas. <i>Lancet, The</i> , 2016, 388, 442-444.	6.3	11
7	Trabectedin for the treatment of soft tissue sarcomas. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1569-1577.	0.9	14
8	Pharmacological therapies for Liposarcoma. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 361-377.	1.3	17
9	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas – an ENITEC Group Initiative. <i>Clinical Cancer Research</i> , 2017, 23, 1274-1285.	3.2	30
10	Approvals in 2016: cost-benefit challenges of new anticancer agents. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 133-134.	12.5	5
11	Approvals in 2016: questioning the clinical benefit of anticancer therapies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 135-136.	12.5	33
12	Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. <i>Lancet Oncology, The</i> , 2017, 18, e166-e175.	5.1	100
13	PDGFRA Antibody for Soft Tissue Sarcoma. <i>Cell</i> , 2017, 168, 555.	13.5	6
14	Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation. <i>Gynecologic Oncology</i> , 2017, 145, 208-216.	0.6	140
15	Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor. <i>Pathology International</i> , 2017, 67, 235-246.	0.6	30
16	Metastatic soft tissue sarcoma: current treatment landscape and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 537-543.	1.1	12
17	Pathology, imaging, and treatment of cardiac tumours. <i>Nature Reviews Cardiology</i> , 2017, 14, 536-549.	6.1	93
18	Treatment options for anthracycline-resistant, advanced soft-tissue sarcoma: the role of eribulin. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 445-453.	0.5	2

#	ARTICLE	IF	CITATIONS
19	Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen. <i>Cancer Research</i> , 2017, 77, 3644-3654.	0.4	55
20	Phase III Soft Tissue Sarcoma Trials: Success or Failure?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 19.	1.3	19
21	Intensity of recent years in the investigation of soft tissue sarcoma. <i>Future Oncology</i> , 2017, 13, 3-9.	1.1	3
22	Review of past and present clinical cases with a view to future treatment options. <i>Future Oncology</i> , 2017, 13, 11-28.	1.1	4
23	Olaratumab for advanced soft tissue sarcoma. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 699-705.	1.3	13
24	Eribulin in advanced liposarcoma and leiomyosarcoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 717-723.	1.1	13
25	CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1751-1764.	1.9	39
26	Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes. <i>Cancer Research</i> , 2017, 77, 4279-4292.	0.4	31
27	Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models. <i>Gynecologic Oncology</i> , 2017, 146, 538-545.	0.6	16
28	Systemic Treatments in Soft Tissue Sarcomas. <i>Clinical Oncology</i> , 2017, 29, 507-515.	0.6	11
30	Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart. <i>Archives of Pharmacal Research</i> , 2017, 40, 875-883.	2.7	31
31	Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey. <i>International Journal of Clinical Oncology</i> , 2017, 22, 541-547.	1.0	2
32	Advances and controversies in the management of soft tissue sarcomas. <i>Future Oncology</i> , 2017, 13, 3-11.	1.1	8
33	Resolution of Multifocal Epstein-Barr Virus-Related Smooth Muscle Tumor in a Patient with GATA2 Deficiency Following Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Immunology</i> , 2017, 37, 61-66.	2.0	20
35	Treatment of soft tissue sarcoma: a focus on earlier stages. <i>Future Oncology</i> , 2017, 13, 13-21.	1.1	26
36	Olaratumab: First Global Approval. <i>Drugs</i> , 2017, 77, 107-112.	4.9	37
37	Evolving biological understanding and treatment of sarcomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 78-80.	12.5	12
38	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , 2017, 111, 108-115.	0.9	11

#	ARTICLE	IF	CITATIONS
39	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1493-1501.	5.1	921
40	PDGF receptors in tumor stroma: Biological effects and associations with prognosis and response to treatment. <i>Advanced Drug Delivery Reviews</i> , 2017, 121, 117-123.	6.6	64
41	Olaratumab for the treatment of soft-tissue sarcoma. <i>Future Oncology</i> , 2017, 13, 2151-2157.	1.1	2
42	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. <i>Oncolimmunology</i> , 2017, 6, e1386829.	2.1	209
43	Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Oncologist</i> , 2016, 22, 1518-1527.	1.9	19
44	PET/Computed Tomography and Precision Medicine. <i>PET Clinics</i> , 2017, 12, 475-488.	1.5	15
45	Aldoxorubicin for the treatment of soft tissue sarcoma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1175-1179.	1.9	19
46	Olaratumab for the treatment of advanced soft tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 883-887.	1.1	0
47	Platelet-Derived Growth Factor Receptor $\hat{\pm}$ Contributes to Human Hepatic Stellate Cell Proliferation and Migration. <i>American Journal of Pathology</i> , 2017, 187, 2273-2287.	1.9	37
48	Olaratumab: PDGFR- $\hat{\pm}$ inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 1-6.	2.0	16
49	Multidisciplinary Management of Sarcomas – Where Are We Now?. <i>Clinical Oncology</i> , 2017, 29, 467-470.	0.6	1
50	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017, 2, e000166.	2.0	4
51	Olaratumab: A Novel Platelet-Derived Growth Factor Receptor $\hat{\pm}$ -Inhibitor for Advanced Soft Tissue Sarcoma. <i>Annals of Pharmacotherapy</i> , 2017, 51, 1090-1098.	0.9	12
52	Randomized Controlled Trials in Soft Tissue Sarcoma: We Are Getting There!. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 531-544.	0.6	5
53	ASCO update – what is new in the systemic treatment of advanced soft tissue sarcomas?. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 233-236.	0.3	0
54	Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 533-550.	1.4	74
55	Emerging drugs for the treatment of gastrointestinal stromal tumour. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 317-329.	1.0	6
56	Hypoxia-activated prodrug: an appealing preclinical concept yet lost in clinical translation. <i>Lancet Oncology, The</i> , 2017, 18, 991-993.	5.1	18

#	ARTICLE	IF	CITATIONS
57	Olaratumab for soft tissue sarcoma. Expert Opinion on Biological Therapy, 2017, 17, 1019-1025.	1.4	4
58	Therapeutic potential of TAS-115 via c-MET and PDGFR \pm signal inhibition for synovial sarcoma. BMC Cancer, 2017, 17, 334.	1.1	10
59	Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Medicine, 2017, 15, 109.	2.3	71
60	Spotlight on landmark oncology trials: the latest evidence and novel trial designs. BMC Medicine, 2017, 15, 111.	2.3	3
61	Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTCâ€™s). Clinical Sarcoma Research, 2017, 7, 10.	2.3	15
62	A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Annals of Oncology, 2017, 28, 121-127.	0.6	24
63	The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients. Expert Review of Vaccines, 2018, 17, 1-8.	2.0	34
64	Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update. Memo - Magazine of European Medical Oncology, 2017, 10, 190-193.	0.3	22
65	The Current Landscape of Early Drug Development for Patients With Sarcoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 807-810.	1.8	3
66	Cytostatic Agents: Monoclonal Antibodies Utilized in the Treatment of Solid Malignancies. Side Effects of Drugs Annual, 2017, 39, 465-482.	0.6	1
67	Uterine sarcoma – current perspectives. International Journal of Women's Health, 2017, Volume 9, 597-606.	1.1	86
68	Appendix 3: Soft tissue sarcoma: MCBS eUpdate published online 5 May 2017 (www.esmo.org/Guidelines/Sarcoma-and-GIST). Annals of Oncology, 2017, 28, iv147-iv148.	0.6	3
69	A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. International Journal of Molecular Sciences, 2017, 18, 1786.	1.8	119
70	Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?. Frontiers in Immunology, 2017, 8, 1245.	2.2	124
71	Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma. Frontiers in Oncology, 2017, 7, 292.	1.3	31
72	Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations. Sarcoma, 2017, 2017, 1-12.	0.7	41
74	Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. OncoTargets and Therapy, 2017, Volume 10, 1155-1164.	1.0	27
75	Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 3579-3587.	2.0	4

#	ARTICLE	IF	CITATIONS
76	Targeted therapy for soft tissue sarcomas in adolescents and young adults. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 41-55.	0.7	11
77	A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US. <i>Clinical Sarcoma Research</i> , 2017, 7, 18.	2.3	9
78	Apoferritin as an ubiquitous nanocarrier with excellent shelf life. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 2265-2278.	3.3	34
79	Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk. <i>EFORT Open Reviews</i> , 2017, 2, 421-431.	1.8	40
80	Olaratumab: a platelet-derived growth factor receptor- α -blocking antibody for the treatment of soft tissue sarcoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 159-164.	0.8	4
81	Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies. <i>Oncotarget</i> , 2017, 8, 104638-104653.	0.8	81
82	Drug Monographs: Olaratumab and Rucaparib. <i>Hospital Pharmacy</i> , 2017, 52, 258-263.	0.4	2
83	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017, 35, 3433-3439.	0.8	126
84	Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma. <i>JAMA Oncology</i> , 2018, 4, 483.	3.4	227
85	Systemic Treatment for Adults with Synovial Sarcoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 13.	1.3	67
86	The challenge of the management of adolescents and young adults with soft tissue sarcomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27013.	0.8	24
87	Olaratumab in soft tissue sarcoma – Current status and future perspectives. <i>European Journal of Cancer</i> , 2018, 92, 33-39.	1.3	16
88	Newer therapeutic strategies for soft-tissue sarcomas. , 2018, 188, 118-123.		5
89	Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 443-458.	12.5	56
90	Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1154-1161.	0.6	35
91	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. <i>Oncologist</i> , 2018, 23, 1250-1259.	1.9	25
92	Leiomyosarcoma of the stomach with metastasis to the liver: a case report with review of the literature. <i>Future Science OA</i> , 2018, 4, FSO264.	0.9	9
94	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC – STBSG). <i>International Journal of Cancer</i> , 2018, 142, 2610-2620.	2.3	32

#	ARTICLE	IF	CITATIONS
95	Options for Adjuvant Therapy for Uterine Leiomyosarcoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 7.	1.3	21
96	Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Oncology</i> , 2018, 29, 857-871.	0.6	55
97	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncology</i> , The, 2018, 19, 416-426.	5.1	517
98	Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) – A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 63, 71-78.	3.4	16
99	Integrative genomic and transcriptomic analysis of leiomyosarcoma. <i>Nature Communications</i> , 2018, 9, 144.	5.8	197
100	Apatinib for advanced sarcoma: results from multiple institutions – off-label use in China. <i>BMC Cancer</i> , 2018, 18, 396.	1.1	54
101	Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. <i>Cancer</i> , 2018, 124, 3819-3829.	2.0	39
102	The current landscape of early drug development for patients with sarcoma in the immunotherapy era. <i>Future Oncology</i> , 2018, 14, 1197-1211.	1.1	11
104	Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma. <i>Future Oncology</i> , 2018, 14, 1531-1545.	1.1	5
105	Current and Future Directions for Angiosarcoma Therapy. <i>Current Treatment Options in Oncology</i> , 2018, 19, 14.	1.3	75
106	Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. <i>Acta Oncologica</i> , 2018, 57, 1117-1126.	0.8	11
107	Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFR α Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer. <i>Clinical Pharmacokinetics</i> , 2018, 57, 355-365.	1.6	21
108	Neurological complications of new chemotherapy agents. <i>Neuro-Oncology</i> , 2018, 20, 24-36.	0.6	28
109	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. <i>International Journal of Cancer</i> , 2018, 142, 1230-1243.	2.3	59
110	Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 157-163.	1.2	14
111	Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 39-49.	1.7	1
112	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. <i>Targeted Oncology</i> , 2018, 13, 81-87.	1.7	8
113	Systemic treatment in adult uterine sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 10-20.	2.0	44

#	ARTICLE	IF	CITATIONS
114	Systemic therapy in retroperitoneal sarcoma management. <i>Journal of Surgical Oncology</i> , 2018, 117, 87-92.	0.8	13
115	EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives. <i>European Journal of Cancer</i> , 2018, 88, 87-91.	1.3	7
116	Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α . <i>Clinical Cancer Research</i> , 2018, 24, 847-857.	3.2	26
117	The PDGF/PDGFR pathway as a drug target. <i>Molecular Aspects of Medicine</i> , 2018, 62, 75-88.	2.7	196
118	Perioperative Management of Extremity Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 118-124.	0.8	33
119	Emerging Targeted and Immune-Based Therapies in Sarcoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 125-135.	0.8	65
120	Multidisciplinary Management of Oligometastatic Soft Tissue Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 939-948.	1.8	24
121	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3324-3330.	0.8	61
122	Soft Tissue and Uterine Leiomyosarcoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 144-150.	0.8	157
123	Synovial Sarcoma: Current Concepts and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2018, 36, 180-187.	0.8	129
124	Clinical and Molecular Spectrum of Liposarcoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 151-159.	0.8	183
125	Integrating therapies for surgical adult soft tissue sarcoma patients. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 88-88.	1.5	4
126	Histology driven systemic therapy of liposarcoma—ready for prime time?. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 96-96.	1.5	4
127	Evolution of the International Sarcoma Community: A Personal Perspective. <i>Oncology</i> , 2018, 95, 1-4.	0.9	7
128	Oncologic orphan drugs approved in the EU—do clinical trial data correspond with real-world effectiveness?. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 214.	1.2	11
129	Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 4-4.	1.5	1
130	Genomic and Proteomic Alterations in Desmoplastic Small Round Blue-Cell Tumors. <i>JCO Precision Oncology</i> , 2018, 2, 1-9.	1.5	10
131	Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	1

#	ARTICLE	IF	CITATIONS
132	First Reported Case of Endoscopic Ultrasound-Guided Core Biopsy Yielding Diagnosis of Primary Adrenal Leiomyosarcoma. <i>Case Reports in Gastrointestinal Medicine</i> , 2018, 2018, 1-3.	0.2	6
133	Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review. <i>Cancers</i> , 2018, 10, 417.	1.7	36
134	Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma. <i>Cancer Science</i> , 2018, 109, 3962-3970.	1.7	7
135	Randomized phase II study of the PDGFR α antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer. <i>BMC Cancer</i> , 2018, 18, 1292.	1.1	27
136	The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov. <i>BMC Cancer</i> , 2018, 18, 1251.	1.1	7
137	Making the Best of Available Options for Optimal Sarcoma Treatment. <i>Oncology</i> , 2018, 95, 11-20.	0.9	16
138	Challenges of Clinical Management of Adolescent and Young Adults With Bone and Soft Tissue Sarcoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 301-306.	1.0	20
139	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. <i>Journal of Hematology and Oncology</i> , 2018, 11, 120.	6.9	333
140	Solitary Fibrous Tumour: A Single Institution Retrospective Study and Further Validation of a Prognostic Risk Assessment System. <i>Clinical Oncology</i> , 2018, 30, 798-804.	0.6	18
141	Uterine leiomyosarcoma: A review of the literature and update on management options. <i>Gynecologic Oncology</i> , 2018, 151, 562-572.	0.6	110
142	Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. <i>Medical Oncology</i> , 2018, 35, 138.	1.2	26
143	Uterine sarcomas. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 51-58.	1.0	109
144	PDGFR α monoclonal antibody: Assessment of embryo-fetal toxicity and time-dependent placental transfer of a murine surrogate antibody of olaratumab in mice. <i>Birth Defects Research</i> , 2018, 110, 1358-1371.	0.8	2
145	Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. <i>Frontiers in Oncology</i> , 2018, 8, 435.	1.3	18
147	Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters. <i>Current Treatment Options in Oncology</i> , 2018, 19, 64.	1.3	19
148	Uterine Leiomyosarcoma. <i>Oncology Research and Treatment</i> , 2018, 41, 680-686.	0.8	35
149	Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. <i>Cardio-Oncology</i> , 2018, 4, .	0.8	10
150	Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report. , 2018, 22, 17-116.		4

#	ARTICLE	IF	CITATIONS
151	Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. <i>Oncologist</i> , 2018, 23, 1533-1545.	1.9	21
152	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , The, 2018, 19, 1360-1371.	5.1	61
153	Advances in the treatment of soft tissue sarcoma: focus on eribulin. <i>Cancer Management and Research</i> , 2018, Volume 10, 207-216.	0.9	9
154	Developments in the management of advanced soft-tissue sarcoma – olaratumab in context. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 833-842.	1.0	13
155	Soft tissue and visceral sarcomas: ESMOâEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
156	Getting up-to-date in the management of soft tissue sarcoma. <i>Future Oncology</i> , 2018, 14, 3-13.	1.1	13
157	Quality of life and patientsâ™ expectations in soft tissue sarcoma. <i>Future Oncology</i> , 2018, 14, 51-62.	1.1	12
158	Epithelioid angiosarcoma: A rare cause of pericarditis and pleural effusion. <i>Respiratory Medicine Case Reports</i> , 2018, 24, 77-80.	0.2	8
159	Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States. <i>Sarcoma</i> , 2018, 2018, 1-14.	0.7	6
160	Targeted Therapyâbased Combination Treatment in Rhabdomyosarcoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1365-1380.	1.9	34
163	PDGF/PDGFR effects in osteosarcoma and the âœadd-onâ•strategy. <i>Clinical Sarcoma Research</i> , 2018, 8, 15.	2.3	28
164	Adult soft tissue sarcoma and time to treatment initiation: An analysis of the National Cancer Database. <i>Journal of Surgical Oncology</i> , 2018, 117, 1776-1785.	0.8	17
165	Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. <i>Clinical Cancer Research</i> , 2018, 24, 5239-5249.	3.2	21
167	Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 777-786.	2.0	37
168	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	2.9	15
169	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e3.	1.0	13
170	A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma. <i>Rare Tumors</i> , 2018, 10, 203636131877177.	0.3	16
171	Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 739.	1.8	44

#	ARTICLE	IF	CITATIONS
172	2018 ESMO Sarcoma and GIST Symposium: "take-home messages"™ in soft tissue sarcoma. ESMO Open, 2018, 3, e000390.	2.0	6
173	KSHV-induced ligand mediated activation of PDGF receptor-alpha drives Kaposi's sarcomagenesis. PLoS Pathogens, 2018, 14, e1007175.	2.1	35
174	Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 536-563.	2.3	457
175	Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas. Clinical Sarcoma Research, 2018, 8, 8.	2.3	16
177	Translational insights into gastrointestinal stromal tumor and current clinical advances. Annals of Oncology, 2018, 29, 2037-2045.	0.6	33
178	Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment. Medical Oncology, 2018, 35, 135.	1.2	14
179	Targeted Therapies in the Treatment of Sarcomas. Targeted Oncology, 2018, 13, 557-565.	1.7	4
180	A possible new pathway in natural killer cell activation also reveals the difficulty in determining human NK cell function in cancer. , 2018, 6, 79.		7
181	Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma. Translational Oncology, 2018, 11, 1271-1282.	1.7	20
182	Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Medical Oncology, 2018, 35, 131.	1.2	14
183	Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research, 2018, 24, 5233-5238.	3.2	214
184	Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma. Future Oncology, 2018, 14, 2323-2333.	1.1	5
185	Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman. Gynecologic Oncology, 2018, 151, 6-9.	0.6	0
186	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma. Clinical Case Reports (discontinued), 2018, 6, 1142-1152.	0.2	9
187	Platelet-derived growth factor receptor- α and β promote cancer stem cell phenotypes in sarcomas. Oncogenesis, 2018, 7, 47.	2.1	28
188	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 2019, 29, 29-39.	2.3	43
189	Olaratumab in the management of advanced soft tissue sarcoma. Journal of Oncology Pharmacy Practice, 2019, 25, 442-448.	0.5	3
190	Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients. Chemotherapy, 2019, 64, 105-109.	0.8	14

#	ARTICLE	IF	CITATIONS
192	Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts. <i>BMC Cancer</i> , 2019, 19, 724.	1.1	6
193	Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. <i>Oncogene</i> , 2019, 38, 6835-6849.	2.6	48
194	A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 919-923.	1.1	4
195	The Combination of Olaratumab with Doxorubicin and Cisplatin Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model. <i>Translational Oncology</i> , 2019, 12, 1257-1263.	1.7	18
196	Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. <i>Journal of Cancer</i> , 2019, 10, 3717-3727.	1.2	46
197	Olaratumab failure in sarcomas: what are the lessons learned?. <i>European Journal of Cancer</i> , 2019, 117, 69-70.	1.3	5
198	Incidence and Management of Olaratumab Infusion-Related Reactions. <i>Journal of Oncology Practice</i> , 2019, 15, e925-e933.	2.5	4
199	<p>&Recent advances and application of PD-1 blockade in sarcoma&. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6887-6896.	1.0	17
200	Sarcoma as a Model for Adolescent and Young Adult Care. <i>Journal of Oncology Practice</i> , 2019, 15, 239-247.	2.5	19
201	A meta-analysis of randomized controlled trials that compare standard doxorubicin with other first-line chemotherapies for advanced/metastatic soft tissue sarcomas. <i>PLoS ONE</i> , 2019, 14, e0210671.	1.1	15
202	Changes in Soft-Tissue Sarcoma Treatment Patterns over Time: A Population-Based Study in a Country with Universal and Centralized Healthcare. <i>Sarcoma</i> , 2019, 2019, 1-7.	0.7	9
203	Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma. <i>PLoS ONE</i> , 2019, 14, e0210731.	1.1	10
204	Patient and Oncologist Preferences for the Treatment of Adults with Advanced Soft Tissue Sarcoma: A Discrete Choice Experiment. <i>Patient</i> , 2019, 12, 393-404.	1.1	5
205	Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model. <i>Biochemical and Biophysical Research Communications</i> , 2019, 509, 1041-1046.	1.0	12
206	Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Nonâ€Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e362-e368.	1.1	5
207	First-Line Therapy for Metastatic Soft Tissue Sarcoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 6.	1.3	73
208	Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development. <i>Cancer Medicine</i> , 2019, 8, 585-592.	1.3	10
209	Investigating a chimeric anti-mouse PDGFRÎ± antibody as a radiosensitizer in primary mouse sarcomas. <i>EBioMedicine</i> , 2019, 40, 224-230.	2.7	6

#	ARTICLE	IF	CITATIONS
210	A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS). <i>Scientific Reports</i> , 2019, 9, 7390.	1.6	3
211	Stem Cells Heterogeneity in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	2
212	Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. <i>Gynecologic Oncology</i> , 2019, 154, 333-337.	0.6	14
213	Future directions in soft tissue sarcoma treatment. <i>Current Problems in Cancer</i> , 2019, 43, 300-307.	1.0	17
214	<p>Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5293-5300.	0.9	12
215	Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Cancer</i> , 2019, 125, 2610-2620.	2.0	47
216	Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 6346-6356.	3.2	75
217	Ovarian Cancer Stem Cell Heterogeneity. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 201-221.	0.8	27
218	Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1503-1515.	0.9	11
219	Multifocal pleomorphic dermal sarcoma and the role of inflammation and immunosuppression in a lung transplant patient: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 169.	0.4	10
220	Contemporary management of metastatic soft tissue sarcoma. <i>Current Problems in Cancer</i> , 2019, 43, 289-299.	1.0	14
221	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. <i>British Journal of Cancer</i> , 2019, 120, 1026-1032.	2.9	33
222	Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy. <i>Biomaterials Science</i> , 2019, 7, 2640-2651.	2.6	34
223	Landmark Trials in Oncology. , 2019, , .		0
224	Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. <i>JAMA Oncology</i> , 2019, 5, 887.	3.4	73
225	Precision Oncology in Sarcomas: Divide and Conquer. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	14
226	The challenge of finding new therapeutic avenues in soft tissue sarcomas. <i>Clinical Sarcoma Research</i> , 2019, 9, 5.	2.3	8
228	Standard treatment and emerging drugs for managing synovial sarcoma: adult™s and pediatric oncologist perspective. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 43-53.	1.0	9

#	ARTICLE	IF	CITATIONS
229	Application of pharmacoeconomics to formulary management in a health system setting. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 381-386.	0.5	6
230	Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. <i>Cancer Letters</i> , 2019, 451, 122-127.	3.2	11
231	Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. <i>Acta Oncologica</i> , 2019, 58, 872-879.	0.8	11
232	PDGFR \pm inhibition in soft-tissue sarcomas: Have we gotten it all wrong?. <i>EBioMedicine</i> , 2019, 40, 37-38.	2.7	2
233	Aldoxorubicin in soft tissue sarcomas. <i>Future Oncology</i> , 2019, 15, 1429-1435.	1.1	12
234	The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1075-1082.	1.1	7
236	Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. <i>Seminars in Cancer Biology</i> , 2019, 59, 3-22.	4.3	29
237	<p>Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2047-2062.	1.0	35
238	Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 713-723.	0.9	12
239	Soft Tissue Sarcoma â€“ a Current Review of the Diagnostic and Treatment Strategies. <i>Zeitschrift Fur Orthopadie Und Unfallchirurgie</i> , 2019, 157, 644-653.	0.4	3
240	A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. <i>Pharmacological Research</i> , 2019, 142, 169-175.	3.1	14
241	Systematic Review of the Current Status of Human Sarcoma Cell Lines. <i>Cells</i> , 2019, 8, 157.	1.8	31
242	Characteristics of mismatch repair deficiency in sarcomas. <i>Modern Pathology</i> , 2019, 32, 977-987.	2.9	49
243	Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Populationâ€Based Study. <i>Oncologist</i> , 2019, 24, e526-e535.	1.9	6
244	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. <i>Oncologist</i> , 2019, 24, 1469-1478.	1.9	25
245	Soft tissue tumours of the elbow: current concepts. <i>EFORT Open Reviews</i> , 2019, 4, 668-677.	1.8	3
246	Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus. <i>Sarcoma</i> , 2019, 2019, 1-14.	0.7	4
247	Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). <i>Oncologist</i> , 2019, 24, e338-e346.	1.9	44

#	ARTICLE	IF	CITATIONS
248	Negative phase III trials announce the need for biomarkers in sarcoma. <i>European Journal of Cancer</i> , 2019, 123, 81-82.	1.3	1
249	Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?. <i>Future Oncology</i> , 2019, 15, 17-23.	1.1	3
250	Update in Pelvic and Retroperitoneal Sarcoma Management: The Role of Compartment Surgery. <i>Cirug�a Espa�ola (English Edition)</i> , 2019, 97, 480-488.	0.1	2
251	Apatinib, combined with chemotherapy or alone is effective in treating angiosarcoma. <i>Anti-Cancer Drugs</i> , 2019, 30, 762-765.	0.7	5
252	Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 46, 337-346.	0.6	4
253	Non-gastrointestinal stromal tumours soft tissue sarcomas: an update. <i>Ecancermedalscience</i> , 2019, 13, 958.	0.6	0
254	A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. <i>Oncologist</i> , 2019, 24, 857-863.	1.9	15
255	Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 107, 186-195.	1.3	11
256	Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 191-199.	1.1	10
257	Optimising Cancer Vaccine Design in Sarcoma. <i>Cancers</i> , 2019, 11, 1.	1.7	211
258	How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers. <i>Current Medical Research and Opinion</i> , 2019, 35, 623-629.	0.9	3
259	Longer heating duration increases localized doxorubicin deposition and therapeutic index in Vx2 tumors using MR-HIFU mild hyperthermia and thermosensitive liposomal doxorubicin. <i>International Journal of Hyperthermia</i> , 2019, 36, 195-202.	1.1	38
260	Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation. <i>BMC Cancer</i> , 2019, 19, 56.	1.1	12
261	Therapeutic Targets for Bone and Soft-Tissue Sarcomas. <i>International Journal of Molecular Sciences</i> , 2019, 20, 170.	1.8	52
262	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4
264	Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 39-50.	1.9	7
265	Immune Checkpoint Inhibitors in Sarcoma. , 2019, , 125-137.		0
266	Bispecific anti-mPDGFR� x cotinine scFv-C�-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFR� expressing cells. <i>Methods</i> , 2019, 154, 125-135.	1.9	9

#	ARTICLE	IF	CITATIONS
267	Current Treatment of Retroperitoneal Sarcomas. Updates in Surgery Series, 2019, , .	0.0	5
268	Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives. Radiologia Medica, 2019, 124, 259-265.	4.7	10
269	Therapeutic Antibodies and Immunologic Conjugates. , 2020, , 486-499.e8.		2
270	Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. Applied Health Economics and Health Policy, 2020, 18, 5-16.	1.0	31
272	Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology. Expert Review of Anticancer Therapy, 2020, 20, 5-8.	1.1	5
273	Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions. , 2020, , .		11
274	Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour. Anti-Cancer Drugs, 2020, 31, 80-84.	0.7	7
275	Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMCâ€³G3) to patients with advanced soft tissue sarcoma. Cancer Medicine, 2020, 9, 882-893.	1.3	3
276	Sarcomas of Soft Tissue. , 2020, , 1655-1693.e11.		0
277	A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. European Journal of Cancer, 2020, 126, 21-32.	1.3	16
278	Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study. Clinical Sarcoma Research, 2020, 10, 18.	2.3	10
279	Heterogeneity of Soft Tissue Sarcomas and Its Implications in Targeted Therapy. Frontiers in Oncology, 2020, 10, 564852.	1.3	14
280	Determinants of the efficacy of viro-immunotherapy: A review. Cytokine and Growth Factor Reviews, 2020, 56, 124-132.	3.2	1
281	A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol). BMC Cancer, 2020, 20, 652.	1.1	4
282	Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab. Clinical Pharmacology and Therapeutics, 2021, 110, 29-31.	2.3	3
283	Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report. Clinical Sarcoma Research, 2020, 10, 10.	2.3	11
284	Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma. BMC Cancer, 2020, 20, 698.	1.1	11
285	Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticleâ€“based Chemotherapy in <i>Pten</i> -deleted Mouse Models of Sarcoma. Clinical Cancer Research, 2020, 26, 5036-5047.	3.2	6

#	ARTICLE	IF	CITATIONS
286	Angiosarcomas of Primary Gynecologic Origin – A Case Series and Review of the Literature. <i>Anticancer Research</i> , 2020, 40, 5743-5750.	0.5	7
287	Synergetic therapy of glioma mediated by a dual delivery system loading \pm -mangostin and doxorubicin through cell cycle arrest and apoptotic pathways. <i>Cell Death and Disease</i> , 2020, 11, 928.	2.7	7
288	Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma. <i>JAMA Oncology</i> , 2020, 6, 1778.	3.4	66
290	Efficacy and safety of anti-angiogenesis medicines for advanced soft tissue sarcoma: a meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 1536-1546.	0.4	3
291	Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. <i>JAMA Network Open</i> , 2020, 3, e2024406.	2.8	53
292	Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. <i>Clinical Sarcoma Research</i> , 2020, 10, 9.	2.3	5
293	Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 446-451.	0.6	4
294	Maintenance therapy and drug holiday in sarcoma patients: systematic review. <i>Acta Oncologica</i> , 2020, 59, 1084-1090.	0.8	7
295	Breakthrough therapy-designated oncology drugs: are they rightfully criticized?. <i>Drug Discovery Today</i> , 2020, 25, 1580-1584.	3.2	3
296	Treatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease. <i>Child's Nervous System</i> , 2020, 36, 2453-2462.	0.6	10
297	Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis. <i>BMC Cancer</i> , 2020, 20, 527.	1.1	16
298	Update on Systemic Therapy for Advanced Soft Tissue Sarcoma. <i>Current Oncology</i> , 2020, 26, .	0.9	2
299	<p>Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1339-1346.	0.9	12
300	ImmunoPET: Concept, Design, and Applications. <i>Chemical Reviews</i> , 2020, 120, 3787-3851.	23.0	263
301	Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices. <i>Sarcoma</i> , 2020, 2020, 1-9.	0.7	2
302	<p>Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 141-146.	0.9	2
303	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	2.0	86
305	Dedifferentiated Liposarcoma: Systemic Therapy Options. <i>Current Treatment Options in Oncology</i> , 2020, 21, 15.	1.3	46

#	ARTICLE	IF	CITATIONS
306	Long lasting response of trabectedin in patient with gastric leiomyosarcoma with liver metastasis: an update to previous report. <i>Future Science OA</i> , 2020, 6, FSO432.	0.9	5
307	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 187-204.	1.0	5
308	Primary Angiosarcoma of the Kidney: Literature Review of a Rare Nosologic Entity. <i>Anticancer Research</i> , 2020, 40, 625-633.	0.5	0
309	Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin. <i>Frontiers in Pharmacology</i> , 2019, 10, 1658.	1.6	27
311	Paratesticular Mesenchymal Malignancies: A Single-Center Case Series, Clinical Management, and Review of Literature. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473541990055.	0.8	5
312	Core needle biopsy versus incisional biopsy for differentiation of soft-tissue sarcomas: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1917-1928.	2.0	46
313	Precision Medicine in Soft Tissue Sarcoma Treatment. <i>Cancers</i> , 2020, 12, 221.	1.7	20
314	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. <i>European Journal of Cancer</i> , 2020, 126, 45-55.	1.3	9
315	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	3.4	125
316	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. <i>Oncolmmunology</i> , 2020, 9, 1703449.	2.1	156
317	Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience. <i>BMC Cancer</i> , 2020, 20, 68.	1.1	4
318	Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours. <i>European Journal of Cancer</i> , 2020, 132, 35-42.	1.3	13
319	Mini-Review on Targeted Treatment of Desmoplastic Small Round Cell Tumor. <i>Frontiers in Oncology</i> , 2020, 10, 518.	1.3	20
320	The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 29-39.	1.1	10
321	TRK inhibition in soft tissue sarcomas: A comprehensive review. <i>Seminars in Oncology</i> , 2020, 47, 73-84.	0.8	9
322	Treatment for Advanced Soft Tissue Sarcoma. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1251.	3.8	1
323	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1266.	3.8	190
324	Sarcomas – A barren immunological wasteland or field of opportunity for immunotherapy?. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 447-470.	0.8	4

#	ARTICLE	IF	CITATIONS
325	Genomic-guided precision therapy for soft tissue sarcoma. <i>ESMO Open</i> , 2020, 5, e000626.	2.0	7
326	Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 3958-3968.	3.2	10
327	Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. <i>European Journal of Cancer</i> , 2020, 130, 72-80.	1.3	18
328	Chimeric antigen receptor-modified T cell therapy for platelet-derived growth factor receptor 1-positive rhabdomyosarcoma. <i>Cancer</i> , 2020, 126, 2093-2100.	2.0	13
329	Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival. <i>Cancer Research</i> , 2020, 80, 2461-2471.	0.4	22
330	Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities. <i>Genes</i> , 2020, 11, 331.	1.0	9
331	Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study. <i>Investigational New Drugs</i> , 2021, 39, 330-336.	1.2	12
332	An ER-targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non-small Cell Lung Cancer. <i>Angewandte Chemie</i> , 2021, 133, 4707-4715.	1.6	28
333	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 132-141.	1.9	9
334	An ER-targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non-small Cell Lung Cancer. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 4657-4665.	7.2	144
335	Surgical Outcomes and Risk Analysis of Primary Pulmonary Sarcoma. <i>Thoracic and Cardiovascular Surgeon</i> , 2021, 69, 101-108.	0.4	4
336	Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies. <i>European Urology Oncology</i> , 2021, 4, 282-288.	2.6	6
337	Olaratumab plus anthracycline in advanced/metastatic soft tissue sarcoma. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 21-25.	1.0	3
338	Chemotherapy and uterine sarcomas: a narrative review. <i>Gynecology and Pelvic Medicine</i> , 0, .	0.1	0
339	Molecular design of peptide amphiphiles for controlled self-assembly and drug release. <i>Journal of Materials Chemistry B</i> , 2021, 9, 3326-3334.	2.9	8
340	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. <i>Current Oncology</i> , 2021, 28, 523-548.	0.9	31
341	Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. <i>Cancer Medicine</i> , 2021, 10, 843-856.	1.3	3
342	PDGF receptor mutations in human diseases. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3867-3881.	2.4	53

#	ARTICLE	IF	CITATIONS
343	Monoclonal Antibodies: A Prospective and Retrospective View. <i>Current Medicinal Chemistry</i> , 2021, 28, 435-471.	1.2	8
344	Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas. <i>Cancer Management and Research</i> , 2021, Volume 13, 1009-1016.	0.9	11
345	AKT1-CREB stimulation of PDGFR α expression is pivotal for PTEN deficient tumor development. <i>Cell Death and Disease</i> , 2021, 12, 172.	2.7	15
346	Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naïve programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study. <i>BMC Cancer</i> , 2021, 21, 108.	1.1	5
347	Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas. <i>ESMO Open</i> , 2021, 6, 100037.	2.0	8
348	Reply to E. Younger et al, V. Sharma et al, and M. Uchihara et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 864-865.	0.8	0
349	Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2021, 27, 3854-3860.	3.2	9
350	Chemotherapy and targeted treatments of breast sarcoma by histologic subtype. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 591-604.	1.1	8
351	A Heat-Activated Drug-Delivery Platform Based on Phosphatidyl-(oligo)-Glycerol Nanocarrier for Effective Cancer Treatment. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000089.	1.7	12
352	Boosting the anticancer activity of doxorubicin with a layered double hydroxide nanocarrier. <i>Applied Clay Science</i> , 2021, 203, 106000.	2.6	18
353	The systemic treatment of uterine leiomyosarcomas. <i>Medicine (United States)</i> , 2021, 100, e25309.	0.4	5
354	Comparison of first line chemotherapy regimens for advanced soft tissue sarcoma: a network meta-analysis. <i>Journal of Chemotherapy</i> , 2021, 33, 570-581.	0.7	2
355	Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study. <i>Anti-Cancer Drugs</i> , 2021, 32, 962-968.	0.7	5
356	Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions. <i>Cancers</i> , 2021, 13, 2359.	1.7	6
357	Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 642683.	1.3	2
358	Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma. <i>Frontiers in Oncology</i> , 2021, 11, 664853.	1.3	44
359	Smart Nanoparticles for Chemo-Based Combinational Therapy. <i>Pharmaceutics</i> , 2021, 13, 853.	2.0	22
360	Advances in siRNA delivery strategies for the treatment of MDR cancer. <i>Life Sciences</i> , 2021, 274, 119337.	2.0	21

#	ARTICLE	IF	CITATIONS
361	Identification of Somatic Genetic Alterations Using Whole-Exome Sequencing of Uterine Leiomyosarcoma Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 687899.	1.3	5
362	Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations. <i>Cancer Medicine</i> , 2021, 10, 5405-5414.	1.3	2
363	Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 152, 165-182.	1.3	60
364	The Role of Natural Killer Cells in Soft Tissue Sarcoma: Prospects for Immunotherapy. <i>Cancers</i> , 2021, 13, 3865.	1.7	4
366	Clinical experience with the treatment of retroperitoneal vascular leiomyosarcoma originating from large veins. <i>BMC Surgery</i> , 2021, 21, 326.	0.6	2
367	The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009–2018. <i>BMC Cancer</i> , 2021, 21, 889.	1.1	5
368	An urgent call to raise the bar in oncology. <i>British Journal of Cancer</i> , 2021, 125, 1477-1485.	2.9	34
370	Synovial sarcoma of the popliteal fossa. <i>Archive of Oncology</i> , 2022, 28, 13-16.	0.2	0
371	Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100275.	0.7	3
372	Olaratumab's failure in soft tissue sarcoma. <i>Rare Tumors</i> , 2021, 13, 203636132110341.	0.3	0
373	Actualizaci3n en el manejo de sarcomas retroperitoneales y p3lvicos; el papel de la cirug3a compartimental. <i>Cirug3a Espa3ola</i> , 2019, 97, 480-488.	0.1	4
375	Glycogen synthase kinase 3 β as a potential therapeutic target in synovial sarcoma and fibrosarcoma. <i>Cancer Science</i> , 2020, 111, 429-440.	1.7	28
376	Potential therapeutic genomic alterations in desmoplastic small round blue cell tumor.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11066-11066.	0.8	2
377	Current status of the adjuvant therapy in uterine sarcoma: A literature review. <i>World Journal of Clinical Cases</i> , 2019, 7, 1753-1763.	0.3	34
378	Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series. <i>PLoS ONE</i> , 2017, 12, e0188116.	1.1	9
379	Metastatic soft tissue sarcomas: update on new agents and clinical studies. <i>Cancer Breaking News</i> , 2017, 5, 5-11.	0.0	1
380	Update on Systemic Therapy for Advanced Soft-Tissue Sarcoma. <i>Current Oncology</i> , 2020, 27, 25-33.	0.9	19
381	Evaluation of immune-biomarker expression in high-grade soft-tissue sarcoma: HLA-DQA1 expression as a prognostic marker. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	16

#	ARTICLE	IF	CITATIONS
382	Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 14, 1-1.	0.4	6
383	Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 1380-1391.	1.3	20
384	Developments in Systemic Therapy for Soft Tissue and Bone Sarcomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 625-628.	2.3	8
385	Olaratumab-induced Biomarker Modulation in Sarcomasâ€™Response. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2094-2094.	1.9	0
386	Olaratumab-induced Biomarker Modulation in Sarcomasâ€™Letter. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2093-2093.	1.9	0
387	<i>nab</i> -Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 3660-3670.	0.8	69
388	Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. <i>Current Problems in Cancer</i> , 2021, 45, 100794.	1.0	4
389	General Statement as to Efficacy of Surgery, Chemotherapy, Radiation Therapy, and Immunotherapy. , 2016, , 41-74.		0
390	Chemotherapy and Other Systemic Approaches to Adult Sarcomas. , 2017, , 223-255.		0
391	Malignome der Weichteile und der Knochen. , 2017, , 881-908.		0
392	Neue Arzneimittel 2016. , 2017, , 55-135.		0
393	Seltene Tumoren des Gastrointestinaltraktes beim alten und geriatrischen Patienten (NET, GIST). , 2017, , 1-18.		0
394	Seltene Tumoren des Gastrointestinaltraktes beim alten und geriatrischen Patienten (NET, GIST). , 2018, , 381-398.		0
396	Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, .	0.2	1
397	Addressing the rarity and complexities of sarcomas. <i>Journal of Community and Supportive Oncology</i> , 2018, 16, e210-e215.	0.1	0
398	Maligne, nichtepitheliale Tumoren des Corpus uteri (ausschlieÃŸlich des Karzinosarkoms). , 2019, , 59-66.		0
399	Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas. <i>F1000Research</i> , 2018, 7, 1737.	0.8	1
400	Chemotherapie, gezielte Tumorthherapie, Immuntherapie. , 2019, , 203-226.		0

#	ARTICLE	IF	CITATIONS
401	Clinical and biological implications of Hippo pathway dysregulation in sarcomas. Forum of Clinical Oncology, 2019, 9, 11-16.	0.1	1
402	Landmark Trials in Selected Adult Soft Tissue Sarcomas. , 2019, , 303-317.		0
403	Retroperitoneale Weichteiltumoren. Springer Reference Medizin, 2019, , 1-13.	0.0	0
404	Medical Therapy in Retroperitoneal Sarcomas. Updates in Surgery Series, 2019, , 133-141.	0.0	0
405	Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series. Precision and Future Medicine, 2019, 3, 77-84.	0.5	0
406	Metastatic Synovial Sarcoma: Experience from a Tertiary Care Center from India. Indian Journal of Medical and Paediatric Oncology, 2019, 40, S95-S98.	0.1	1
407	Systematic review of anorectal leiomyosarcoma: Current challenges and recent advances. World Journal of Gastrointestinal Surgery, 2019, 11, 334-341.	0.8	8
408	Dermatofibrosarcoma metastases to the pancreas: A case report. World Journal of Clinical Cases, 2019, 7, 3316-3321.	0.3	1
409	Chemotherapy of Soft Tissue Sarcomas. , 2020, , 323-325.		0
410	Sarcomas. , 2020, , 47-59.		0
411	Construction and Validation of Nomograms for Predicting the Prognosis of Uterine Leiomyosarcoma: A Population-Based Study. Medical Science Monitor, 2020, 26, e922739.	0.5	10
412	Developing Drugs for Sarcomas in a Brave New World. Journal of Immunotherapy and Precision Oncology, 2020, 3, 62-63.	0.6	0
413	SMARCB1/INI1-deficient tumors of adulthood. F1000Research, 2020, 9, 662.	0.8	2
414	A Case Report of Epithelioid Angiosarcoma That Rapidly Enlarged Three Months After Detection at a Health Checkup. Japanese Journal of Lung Cancer, 2020, 60, 207-211.	0.0	0
415	SMARCB1/INI1-deficient tumors of adulthood. F1000Research, 2020, 9, 662.	0.8	11
416	Advances in soft-tissue sarcoma “ There are no mistakes, only lessons to learn!. South Asian Journal of Cancer, 2019, 08, 258-259.	0.2	2
417	Pazopanib in Soft Tissue Sarcomas. Oncology & Hematology Review, 2020, 16, 15.	0.2	0
419	Therapy Response Imaging in Sarcoma and Musculoskeletal Malignancies. Medical Radiology, 2020, , 201-217.	0.0	0

#	ARTICLE	IF	CITATIONS
420	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
421	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. Journal of Gynecologic Oncology, 0, 29, .	1.0	0
423	Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis “ a systematic literature review. EFORT Open Reviews, 2020, 5, 799-814.	1.8	15
424	Olaratumab (Lartruvo): An Innovative Treatment for Soft Tissue Sarcoma. P and T, 2018, 43, 267-270.	1.0	4
425	Metastatic Soft Tissue Sarcomas: A Review Of Treatment and New Pharmacotherapies. P and T, 2018, 43, 410-429.	1.0	22
426	Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma. Journal of the Advanced Practitioner in Oncology, 2018, 9, 235-240.	0.2	1
427	Angiosarcoma: a review of diagnosis and current treatment. American Journal of Cancer Research, 2019, 9, 2303-2313.	1.4	35
428	SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treatment Reviews, 2022, 102, 102312.	3.4	29
429	miR-197-5p increases Doxorubicin-mediated anticancer cytotoxicity of HT1080 fibrosarcoma cells by decreasing drug efflux. DNA Repair, 2022, 109, 103259.	1.3	9
430	British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 270, 50-89.	0.5	46
431	Facilitating drug delivery in the central nervous system by opening the blood-cerebrospinal fluid barrier with a single low energy shockwave pulse. Fluids and Barriers of the CNS, 2022, 19, 3.	2.4	17
432	Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas. Frontiers in Oncology, 2021, 11, 778774.	1.3	2
433	Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years. Cancers, 2022, 14, 889.	1.7	12
434	Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit. Cancer Investigation, 2022, 40, 184-188.	0.6	4
435	Personalised pharmacotherapy options for soft tissue sarcomas. Expert Review of Precision Medicine and Drug Development, 2022, 7, 17-28.	0.4	1
436	Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas. Current Treatment Options in Oncology, 2022, 23, 78-88.	1.3	10
437	Co-delivery of anticancer drugs via poly(ionic crosslinked chitosan-palladium) nanocapsules: Targeting more effective and sustainable cancer therapy. Journal of Drug Delivery Science and Technology, 2022, 69, 103151.	1.4	15
438	Developing a translational murine“canine pathway for an <sc>IL</sc>“agonist <sc>anti“CD40</sc> antibody cancer immunotherapy. Veterinary and Comparative Oncology, 2022, 20, 602-612.	0.8	4

#	ARTICLE	IF	CITATIONS
439	Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials. <i>ESMO Open</i> , 2022, 7, 100425.	2.0	2
440	2D-ultrathin MXene/DOXjade platform for iron chelation chemo-photothermal therapy. <i>Bioactive Materials</i> , 2022, 14, 76-85.	8.6	42
441	Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. <i>Frontiers in Immunology</i> , 2021, 12, 775761.	2.2	45
442	PET imaging of mitochondrial function in acute doxorubicin-induced cardiotoxicity: a proof-of-principle study. <i>Scientific Reports</i> , 2022, 12, 6122.	1.6	7
452	Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 822469.	1.3	3
453	Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1703-1711.	0.9	3
454	Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context. <i>Cancers</i> , 2022, 14, 2446.	1.7	32
455	Platelets involved tumor cell EMT during circulation: communications and interventions. <i>Cell Communication and Signaling</i> , 2022, 20, .	2.7	16
456	Introduction to the management of soft tissue sarcomas. , 2023, , 393-402.		0
457	First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: A prospective, single-arm trial. <i>Asian Pacific Journal of Tropical Medicine</i> , 2022, 15, 266.	0.4	1
458	Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden. <i>Cancer</i> , 0, , .	2.0	0
459	Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
460	In search of effective therapies: the current landscape of phase II trials in patients with advanced soft tissue sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
461	The role of imaging in targeted delivery of nanomedicine for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114447.	6.6	24
462	Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis. <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 927-935.	0.8	2
463	BQ-AurIPr: a redox-active anticancer Au($\text{Au}(\text{Au})$) complex that induces immunogenic cell death. <i>Chemical Science</i> , 2022, 13, 10779-10785.	3.7	7
464	Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments. <i>Current Oncology</i> , 2022, 29, 5774-5791.	0.9	10
465	New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC " Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas. <i>European Journal of Cancer</i> , 2022, 174, 261-276.	1.3	8

#	ARTICLE	IF	CITATIONS
466	Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations. <i>Contemporary Clinical Trials Communications</i> , 2022, 30, 101000.	0.5	5
467	<i>Viszeralchirurgie.</i> , 2022, , 223-437.		0
468	Radiation Therapy for Oligometastatic Sarcomas. <i>Practical Guides in Radiation Oncology</i> , 2022, , 77-110.	0.0	0
469	Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 5280-5289.	3.2	10
470	Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 5290-5296.	3.2	6
471	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
472	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
473	Temperature- and pH-responsive injectable chitosan hydrogels loaded with doxorubicin and curcumin as long-lasting release platforms for the treatment of solid tumors. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	9
474	Targeted therapy and molecular genetics. , 2023, , 464-488.e11.		0
475	Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5473.	1.7	4
476	Integrated Analysis of TME and Hypoxia Identifies a Classifier to Predict Prognosis and Therapeutic Biomarkers in Soft Tissue Sarcomas. <i>Cancers</i> , 2022, 14, 5675.	1.7	1
477	Drugs In The GIST Field (Therapeutic Targets And Clinical Trial Staging). <i>Current Drug Delivery</i> , 2022, 20, .	0.8	0
478	Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	4
479	Targeted therapies for soft tissue sarcomas and desmoid tumors. <i>Sarkomy Kosteji, MÃƒgkih Tkaneji Opuholi KoÅ¾i</i> , 2022, 14, 13-21.	0.0	0
480	Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARCO21/TH CR-406). <i>Clinical Cancer Research</i> , 2023, 29, 1068-1076.	3.2	2
481	A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma. <i>Current Treatment Options in Oncology</i> , 2023, 24, 212-228.	1.3	1
482	Management and Outcomes of Older Patients (Age ≥ 70 Years) with Advanced Soft Tissue Sarcoma and Role of Geriatric Assessment and Oncological Multidimensional Prognostic Index (Onco-MPI) in a Real-World Setting. <i>Cancers</i> , 2023, 15, 1043.	1.7	1
483	The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020. <i>International Journal of Cancer</i> , 2023, 152, 2474-2484.	2.3	11

#	ARTICLE	IF	CITATIONS
484	The biology and treatment of leiomyosarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103955.	2.0	1
485	Therapeutic advances in leiomyosarcoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	7
486	<scp>PDGFRÎ±</scp> monoclonal antibody: Assessment of toxicity in juvenile mice administered a murine surrogate antibody of olaratumab. <i>Birth Defects Research</i> , 2023, 115, 782-796.	0.8	0
487	Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC). <i>Current Oncology</i> , 2023, 30, 3637-3647.	0.9	1
489	Anticancer drugs acting on signaling pathways, part 1: Tyrosine kinase inhibitors. , 2023, , 493-563.		0
491	Angiogenic signaling pathways and anti-angiogenic therapy for cancer. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	68
500	Leiomyosarcoma, Endometrial Stromal Sarcoma, Undifferentiated Stromal Sarcomas, Adenosarcoma, Smooth Muscle Tumor of Unknown Malignant Potential. , 2023, , 227-240.		0
501	Chemokine and Cytokine Network in Angiogenesis. , 2023, , 79-114.		0
507	Lessons from withdrawn accelerated approvals in oncology. <i>Nature Cancer</i> , 2024, 5, 211-215.	5.7	0